The Global Car-T Cell Therapy Market Is Expected to Be Valued at Us$ 7.7 Billion by 2028, Owing to Increasing Prevalence of Cancer

Global CAR-T Cell Therapy Market Projected to Reach $7.7 Billion by 2028

A chimeric antigen receptor (CAR)-T cell therapy is a type of treatment in which a patient’s T cells, lymphocytes of a type produced or processed by the thymus gland and actively participating in the immune response, are modified to attack cancer cells.

Increasing prevalence of cancer is expected to boost growth of the global CAR-T cell therapy market over the forecast period. For instance, according to the World Health Organization, around 18.1 million new cases and 9.6 million deaths were registered due to cancer worldwide in 2018. Moreover, increasing preference for genetically engineered treatment approaches for the effective treatment of various types of cancers is also expected to aid in growth of the market.

Increasing investments related to CAR-T cell therapy are expected to fuel growth of the global CAR-T cell therapy market over the forecast period. For instance, in 2016, Novartis International AG invested around US$ 9 billion in R&D in CAR-T cell therapy. Other companies that are actively involved in R&D in CAR-T cell therapy for diffuse large B-cell lymphoma and relapsed/refractory acute lymphoblastic leukemia include Juno Therapeutics and Kite Pharma Inc.

Request for a Sample Copy Here

Among regions, North America is expected to hold dominant position in the global CAR-T cell therapy market over the forecast period. This is owing to increasing prevalence of cancer in the region. For instance, according to Fight Colorectal Cancer Organization, there will be an estimated 140,250 new cases of colorectal cancer in 2019 in the U.S.

Europe is expected to follow North America in terms of market share. However, conducting country-specific clinical trials across the region is expected to be a major challenge for growth of the market.

Among the types of therapy, the CD 19-based therapy segment is expected to hold dominant position in the global CAR-T cell therapy market over the forecast period. This is owing to increasing R&D related to CD 19 for the treatment of leukemia. Other antigens such as CD 20 and CD 22 are also expected to witness significant growth.

Major players in the market are focused on conducting clinical trials to expand their product portfolio. For instance, in February 2020, Precision BioSciences announced its plan to initiate a clinical trial for its new CAR T-cell therapy candidate, PBCAR269A, for the treatment of relapsed or refractory multiple myeloma. The Phase 1/2a trial (NCT04171843) is expected to begin enrolling eligible adults in March at multiple U.S. sites. Moreover, in March 2020, Tessa Therapeutics received the U.S. Food and Drug Administration (FDA)’s Regenerative Medicine Advanced Therapy designation to its investigational CD30-targeted CAR T-cell therapy for the treatment of relapsed or refractory classical Hodgkin’s lymphoma.

Get Flat USD 2000 OFF

Buy-Now this research report: https://www.coherentmarketinsights.com/promo/buynow/102

Reasons to Purchase this Report

• Current and future of global Lab-on-a-chip Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period.
• The latest developments, market shares, and strategies that are employed by the major market players.

Key Takeaways

• Increasing prevalence of cancer to augment growth of the global CAR-T cell therapy market over the forecast period
• North America is expected to account for 58.3% of overall industry share in 2018
• CD 19 segment is expected to touch a billion dollar mark by 2023
• Major players operating in the global CAR-T cell therapy market include, Novartis International AG, Kite Pharma, Inc. (Gilead Sciences, Inc.), Juno Therapeutics (Celgene Corporation), Bluebird Bio, Inc. (Celgene Corporation), Sorrento Therapeutics Inc., Mustang Bio, Inc., Aurora Biopharma Inc., Legend Biotech (Genscript Biotech Corporation), Pfizer, Inc., CARsgen Therapeutics, Ltd., and others.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

Contact:

Coherent Market Insights

1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Email: sales@coherentmarketinsights.com

United States of America: +1-206-701-6702

United Kingdom: +44-020-8133-4027

Japan: +050-5539-1737

India: +91-848-285-0837

The post The Global CAR-T Cell Therapy Market is expected to be valued at US$ 7.7 Billion by 2028, Owing To Increasing Prevalence of Cancer appeared first on Gatorledger.